XT-150

About Xalud Therapeutics

Xalud Therapeutics is pioneering a non-viral gene therapy platform targeting chronic inflammation, a root cause of many prevalent diseases. Its lead candidate, XT-150, delivers a modified IL-10 cytokine via plasmid DNA and is being evaluated in multiple indications, including osteoarthritis and facet joint syndrome, with a completed Phase 2b trial. The company's technology aims to expand gene therapy access beyond rare monogenic conditions to address widespread chronic inflammatory and neurodegenerative diseases with high unmet need. Xalud represents a novel approach by aiming to restore immune balance locally with a potentially durable and redosable therapy.

About Xalud Therapeutics

Xalud Therapeutics is pioneering a non-viral gene therapy platform targeting chronic inflammation, a root cause of many prevalent diseases. Its lead candidate, XT-150, delivers a modified IL-10 cytokine via plasmid DNA and is being evaluated in multiple indications, including osteoarthritis and facet joint syndrome, with a completed Phase 2b trial. The company's technology aims to expand gene therapy access beyond rare monogenic conditions to address widespread chronic inflammatory and neurodegenerative diseases with high unmet need. Xalud represents a novel approach by aiming to restore immune balance locally with a potentially durable and redosable therapy.

Therapeutic Areas

Other Osteoarthritis of the knee Drugs